Moleculin Biotech (MBRX) Depreciation & Amortization (IS) (2016 - 2025)
Moleculin Biotech (MBRX) has 10 years of Depreciation & Amortization (IS) data on record, last reported at $22000.0 in Q3 2025.
- For Q3 2025, Depreciation & Amortization (IS) fell 29.03% year-over-year to $22000.0; the TTM value through Sep 2025 reached $112000.0, down 13.18%, while the annual FY2024 figure was $126000.0, 0.79% down from the prior year.
- Depreciation & Amortization (IS) reached $22000.0 in Q3 2025 per MBRX's latest filing, down from $28000.0 in the prior quarter.
- Across five years, Depreciation & Amortization (IS) topped out at $44000.0 in Q1 2021 and bottomed at $22000.0 in Q3 2025.
- Average Depreciation & Amortization (IS) over 5 years is $33000.0, with a median of $32000.0 recorded in 2022.
- Peak YoY movement for Depreciation & Amortization (IS): increased 9.38% in 2023, then decreased 29.03% in 2025.
- A 5-year view of Depreciation & Amortization (IS) shows it stood at $34000.0 in 2021, then dropped by 5.88% to $32000.0 in 2022, then rose by 9.38% to $35000.0 in 2023, then dropped by 11.43% to $31000.0 in 2024, then fell by 29.03% to $22000.0 in 2025.
- Per Business Quant database, its latest 3 readings for Depreciation & Amortization (IS) were $22000.0 in Q3 2025, $28000.0 in Q2 2025, and $31000.0 in Q1 2025.